Product Images Ticagrelor
View Photos of Packaging, Labels & Appearance
- c7aeae20-figure-01 - c7aeae20 figure 01
- c7aeae20-figure-02 - c7aeae20 figure 02
- C:\Users\RA\Desktop\Untitled.jpg - c7aeae20 figure 03
- c7aeae20-figure-05 - c7aeae20 figure 04
- c7aeae20-figure-06 - c7aeae20 figure 05
- figure7 - c7aeae20 figure 06
- figure-08 - c7aeae20 figure 07
- c7aeae20-figure-09 - c7aeae20 figure 08
- c7aeae20-figure-10 - c7aeae20 figure 09
- c7aeae20-figure-11 - c7aeae20 figure 10
- c7aeae20-figure-12 - c7aeae20 figure 11
- figure 13 - c7aeae20 figure 12
- 90 mg 60 ct - c7aeae20 figure 14
- figure4 - image 02
- figure17 - image 05
- figure 18 - image 06
Product Label Images
The following 16 images provide visual information about the product associated with Ticagrelor NDC 43547-657 by Solco Healthcare U.s., Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
c7aeae20-figure-01 - c7aeae20 figure 01
Not available.*
c7aeae20-figure-02 - c7aeae20 figure 02
C:\Users\RA\Desktop\Untitled.jpg - c7aeae20 figure 03
c7aeae20-figure-05 - c7aeae20 figure 04
c7aeae20-figure-06 - c7aeae20 figure 05
figure7 - c7aeae20 figure 06
This text provides information on dose adjustments for Ticagrelor (AR-C124010XX) based on intrinsic factors such as age, gender, ethnicity, renal disease status, and hepatic impairment. The data includes recommendations for dose adjustments or no adjustment for different conditions or demographics. It also mentions the lack of studies involving Ticagrelor tablets in patients with moderate or severe hepatic impairment.*
figure-08 - c7aeae20 figure 07
This text provides information on the mean effect and 90% Confidence Interval interactions of the drug Ticagrelor with various interacting drugs. It categorizes the recommendations for Strong CYP3A4 inhibitors like Ketoconazole and Potent CYP3A4 inducers like Rifampin as "Avoid concomitant use," while suggesting no dose adjustment for Moderate CYP3A4 inhibitors such as Diltiazem. Additionally, guidelines are given for other medications like Aspirin, Desmopressin, Heparin, and Enoxaparin regarding dose adjustments or concomitant use. The interaction information for P-gP and CYP3A inhibitors like Cyclosporine, Morphine, and Fentanyl is also detailed, with further reference to Section 7.4 for specific details.*
c7aeae20-figure-09 - c7aeae20 figure 08
This text provides information on interactions between Ticagrelor and several other drugs such as Simvastatin, Atorvastatin, Lovonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, specifying the recommended dose adjustments and potential effects on drug levels. It also mentions to monitor digoxin levels when initiating or changing Ticagrelor therapy.*
c7aeae20-figure-10 - c7aeae20 figure 09
c7aeae20-figure-11 - c7aeae20 figure 10
c7aeae20-figure-12 - c7aeae20 figure 11
figure 13 - c7aeae20 figure 12
90 mg 60 ct - c7aeae20 figure 14
Each tablet contains 90 mg of ticagrelor. The usual adult dosage should be confirmed by referring to the package insert. Remember to keep this medication out of the reach of children. Store it at a temperature between 20°C - 25°C (68°F - 77°F), with permitted excursions to 15°C - 30°C (59°F - 86°F) as per USP Controlled Room Temperature guidelines. You can access the Medication Guide online at www.solcohealthcare.com/medguide/ticagrelor-tablets.pdf. This medication is manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. in China and distributed by Solco Healthcare US, LLC in the USA.*
figure4 - image 02
figure17 - image 05
figure 18 - image 06
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
